R.NyhanD.et al (2006)
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

=========================================== WELCOME REMARKS Nancy Reynolds Chair, CUGH, Associate Dean Global Affairs, Johns Hopkins School of Nursing Rebecca Martin Vice President for Global Health & Director of the Emory Global Health Institute, Emory University Juliet Sekandi Associate Director, Global Health Institute, University of Georgia Anna Helova Deputy Director, Sparkman Center for Global Health, University of Alabama Birmingham Keith Martin Executive Director, CUGH =========================================== KEYNOTE PRESENTATION: What the Global Health Community Can Do to Improve Public Health Outcomes Across the Americas Given the Rise in NCD's Introduction by: Kristie Mikus Executive Director, Global Health Technologies Coalition Moderator: Kristie Mikus, Executive Director, Global Health Technologies Coalition Panelists: Rhonda Sealey-Thomas Assistant Director, Pan-American Health Organization (PAHO) =========================================== Rhonda Sealey-Thomas Assistant Director Pan American Health Organization (PAHO) Kristie Mikus Executive Director, Global Health Technologies Coalition Support our young researchers and visit their interesting posters in the 'Galleria' (Lower Level)

Melanotan 2 : Possible pigmentation changes, transient nausea, and facial flushing have been documented in research settings
Hou, X., Rooklin, D., Fang, H